{"id":12752,"date":"2017-11-29T09:24:19","date_gmt":"2017-11-29T09:24:19","guid":{"rendered":"https:\/\/celonpharma.com\/?page_id=12752"},"modified":"2026-07-09T12:42:29","modified_gmt":"2026-07-09T10:42:29","slug":"shareholding-structure","status":"publish","type":"page","link":"https:\/\/celonpharma.com\/en\/shareholding-structure\/","title":{"rendered":"Shareholders Structure"},"content":{"rendered":"\n
\"\"<\/figure>\n\n\n\n

(i) Glatton sp. z o.o. held 15,000,000 registered shares with preferential voting rights.<\/p>\n\n\n\n

(ii) of which Generali OFE held 4,032,424 shares of the Company, representing 7.5% of its share capital and entitling it to exercise 4,032,424 votes at its general meeting, i.e. 5.9% of the total number of votes in the Company.<\/p>\n\n\n\n

(iii) of which Tang Capital Partners, LP, after subscribing for series E shares (current report No. 15\/2024) and after their registration with the National Court Register (KRS) on August 6, 2024 (current report No. 18\/2024), held 2,700,000 shares of the Company, representing 5.0% of its share capital and entitling it to exercise 2,700,000 votes at its general meeting, i.e. 3.9% of the total number of votes in the Company.<\/p>\n\n\n\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

(i) Glatton sp. z o.o. held 15,000,000 registered shares with preferential voting rights. (ii) of which Generali OFE held 4,032,424 shares of the Company, representing 7.5% of its share capital and entitling it to exercise 4,032,424 votes at its general meeting, i.e. 5.9% of the total number of votes in the Company. (iii) of whichRead more »<\/a><\/p>\n","protected":false},"author":11,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"footnotes":""},"class_list":["post-12752","page","type-page","status-publish","hentry"],"acf":[],"yoast_head":"\nShareholders Structure - Celon Pharma<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/celonpharma.com\/en\/shareholding-structure\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Shareholders Structure - Celon Pharma\" \/>\n<meta property=\"og:description\" content=\"(i) Glatton sp. z o.o. held 15,000,000 registered shares with preferential voting rights. (ii) of which Generali OFE held 4,032,424 shares of the Company, representing 7.5% of its share capital and entitling it to exercise 4,032,424 votes at its general meeting, i.e. 5.9% of the total number of votes in the Company. (iii) of whichRead more »\" \/>\n<meta property=\"og:url\" content=\"https:\/\/celonpharma.com\/en\/shareholding-structure\/\" \/>\n<meta property=\"og:site_name\" content=\"Celon Pharma\" \/>\n<meta property=\"article:modified_time\" content=\"2026-07-09T10:42:29+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/celonpharma.com\/wp-content\/uploads\/2026\/07\/Delta-View-3.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1024\" \/>\n\t<meta property=\"og:image:height\" content=\"1024\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/shareholding-structure\\\/\",\"url\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/shareholding-structure\\\/\",\"name\":\"Shareholders Structure - Celon Pharma\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/shareholding-structure\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/shareholding-structure\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/celonpharma.com\\\/wp-content\\\/uploads\\\/2026\\\/07\\\/Delta-View-3.png\",\"datePublished\":\"2017-11-29T09:24:19+00:00\",\"dateModified\":\"2026-07-09T10:42:29+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/shareholding-structure\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/celonpharma.com\\\/en\\\/shareholding-structure\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/shareholding-structure\\\/#primaryimage\",\"url\":\"https:\\\/\\\/celonpharma.com\\\/wp-content\\\/uploads\\\/2026\\\/07\\\/Delta-View-3.png\",\"contentUrl\":\"https:\\\/\\\/celonpharma.com\\\/wp-content\\\/uploads\\\/2026\\\/07\\\/Delta-View-3.png\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/shareholding-structure\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Shareholders Structure\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/\",\"name\":\"Celon Pharma\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Shareholders Structure - Celon Pharma","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/celonpharma.com\/en\/shareholding-structure\/","og_locale":"en_US","og_type":"article","og_title":"Shareholders Structure - Celon Pharma","og_description":"(i) Glatton sp. z o.o. held 15,000,000 registered shares with preferential voting rights. (ii) of which Generali OFE held 4,032,424 shares of the Company, representing 7.5% of its share capital and entitling it to exercise 4,032,424 votes at its general meeting, i.e. 5.9% of the total number of votes in the Company. (iii) of whichRead more »","og_url":"https:\/\/celonpharma.com\/en\/shareholding-structure\/","og_site_name":"Celon Pharma","article_modified_time":"2026-07-09T10:42:29+00:00","og_image":[{"width":1024,"height":1024,"url":"https:\/\/celonpharma.com\/wp-content\/uploads\/2026\/07\/Delta-View-3.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/celonpharma.com\/en\/shareholding-structure\/","url":"https:\/\/celonpharma.com\/en\/shareholding-structure\/","name":"Shareholders Structure - Celon Pharma","isPartOf":{"@id":"https:\/\/celonpharma.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/celonpharma.com\/en\/shareholding-structure\/#primaryimage"},"image":{"@id":"https:\/\/celonpharma.com\/en\/shareholding-structure\/#primaryimage"},"thumbnailUrl":"https:\/\/celonpharma.com\/wp-content\/uploads\/2026\/07\/Delta-View-3.png","datePublished":"2017-11-29T09:24:19+00:00","dateModified":"2026-07-09T10:42:29+00:00","breadcrumb":{"@id":"https:\/\/celonpharma.com\/en\/shareholding-structure\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/celonpharma.com\/en\/shareholding-structure\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/celonpharma.com\/en\/shareholding-structure\/#primaryimage","url":"https:\/\/celonpharma.com\/wp-content\/uploads\/2026\/07\/Delta-View-3.png","contentUrl":"https:\/\/celonpharma.com\/wp-content\/uploads\/2026\/07\/Delta-View-3.png"},{"@type":"BreadcrumbList","@id":"https:\/\/celonpharma.com\/en\/shareholding-structure\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/celonpharma.com\/en\/"},{"@type":"ListItem","position":2,"name":"Shareholders Structure"}]},{"@type":"WebSite","@id":"https:\/\/celonpharma.com\/en\/#website","url":"https:\/\/celonpharma.com\/en\/","name":"Celon Pharma","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/celonpharma.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"_links":{"self":[{"href":"https:\/\/celonpharma.com\/en\/wp-json\/wp\/v2\/pages\/12752","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/celonpharma.com\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/celonpharma.com\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/celonpharma.com\/en\/wp-json\/wp\/v2\/users\/11"}],"replies":[{"embeddable":true,"href":"https:\/\/celonpharma.com\/en\/wp-json\/wp\/v2\/comments?post=12752"}],"version-history":[{"count":2,"href":"https:\/\/celonpharma.com\/en\/wp-json\/wp\/v2\/pages\/12752\/revisions"}],"predecessor-version":[{"id":44430,"href":"https:\/\/celonpharma.com\/en\/wp-json\/wp\/v2\/pages\/12752\/revisions\/44430"}],"wp:attachment":[{"href":"https:\/\/celonpharma.com\/en\/wp-json\/wp\/v2\/media?parent=12752"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}